Figure 4From: Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritisAnti-cytokine treatment interferes with the performance of Pentraxin-3 (PTX3) as a biomarker in Takayasu arteritis (TA). (A-C) Plasma PTX3, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) levels in patients with TA without anti-cytokine therapy, stratified according to the presence of vascular wall enhancement after contrast medium infusion. (D-F) Concentrations of PTX3, CRP and ESR in patients with TA without anti-cytokine therapy, stratified according to the progression of vascular wall involvement on longitudinal imaging follow up.Back to article page